Sound like a delicate flower, but they OK when JPeckehead
Sound like a delicate flower, but they OK when JPeckehead stamps all over their garden?
For no reason?
Not sure how many times a RS has to be discussed and people get bent each time they bring it up as if it was the first time it's been discussed.
Those that get all bent, maybe create a FAQ for new investors instead of crying. As you learn things, add them to the FAQ. You'd get a ton of respect than.
These are 'investors' that have been around a while too. I guess I sort of get it as they can't even remember when earnings are even though it's also been said a number of times and actually quicker to do a google search than to keep asking. They could put that in the FAQ too.
Gerald has said many times, there would be no RS at these levels. Who in their right mind would RS a .03 stock? The only way a RS would work is if you had a ton of revenues or solid product(s) that would drive revenue shortly after you uplisted.
You can't uplist and then do something years from now. WE ALL know that, but doesn't stop people that either are new to investing or way over their skis to want to bring it up every week. If they didn't figure it out yet, that is in the official Assclown playbook for all stocks...
1. Bring up RS weekly
2. Bring up Dilution weekly
3. Mention the stock is going to trips
4. Call the CEO names
5. Tell everyone how you can run the company better
6. Respond to everyone that mentions a short-term catalysts that... it will never happen
7. Bring up RS weekly
See, it's even in there twice
I wouldn't' even ask...at want sp would you RS?
Better question:
What milestones would you complete before uplisting?
Penny traders like to speak to everything based on the sp. The sp is going to .01. The sp is going to a $1. But they don't even know what that means or what would trigger that. In their head it's all relative to the current sp. It's like clay in every video saying the sp might go up, the sp might go down. Yeah, no shit genius. Don't need to take your $2K class to here that garbage.
Smart investors see it different.
So what milestones should be completed before uplisting, is what true investors should be thinking and oh, it has nothing to do with the sp.
I can rattle off a bunch and only need a few or depending on which one, only one to hit. Whether the sp is at .10 or a $1 in that case, the RS wouldn't matter.
Now you have a few CytoDyn followers as mods there. I hope CytoDyn can take off as they have drugs in a number important areas in phase II & III. But it would be the same question for any stock including CytoDyn, what milestones would need to be completed before uplisting. Today they have very little revenue and could be a death sentence if that wasn't one of them. I could tell you what I would need to see before investing a penny there but this is the Todos board anyway.
1
Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...
Continue Reading
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...
Continue Reading
A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...
Continue Reading
Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...
Continue Reading
Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...
Continue Reading
A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...
Continue Reading
Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...
Continue Reading
Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...
Continue Reading
Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...
Continue Reading
Top 5 Most Recently Viewed Articles
3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...
Continue Reading
Uganda's government announced a hefty shift in its fiscal playbook back in 2024, aiming to cut spending by over 20% and slash domestic borrowing by more than half for the upcoming 2025/26 fiscal year. This wasn’t just some routine budgetary tweak; it was a necessary maneuver amidst growing alarm about the nation's spiraling public debt. You know these moves grab...
Continue Reading
Vivos Therapeutics Prepares for Q1 2025 Financial Disclosure Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneering company in the medical devices sector, is gearing up to release its financial results for the first quarter of 2025. This announcement is anticipated to take place following the market's closure on a Thursday in May 2025. The management team is set to hold a...
Continue Reading
XBP Global Welcomes You to the 11th Annual Turkey Trot XBP Global Holdings, Inc. (NASDAQ: XBP) is thrilled to invite the community to the 11th Annual Palisades Turkey Trot, a cherished tradition returning this Thanksgiving morning. Held at Palisades Green, this year's event promises excitement with new 5K and 10K courses that enhance the festive atmosphere of the...
Continue Reading
Boot Barn Stock Forecast Amid CEO Transition and Solid Performance In the latest developments regarding Boot Barn (NYSE: BOOT), analysts at Craig-Hallum have made notable adjustments to their stock price outlook. The price target has been revised to $160 from a previous $162, maintaining a Hold rating. The adjustments come in light of the company's impressive performance...
Continue Reading